Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards to purchase up to 167,400 shares of common stock to 11 new employees under the Company’s 2023 Inducement Plan on September 1, 2025. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee’s continued service relationship with Syndax. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies, with an FDA-approved menin inhibitor and monoclonal antibody in its pipeline. For more information, visit www.syndax.com. Contact Sharon Klahre at [email protected] or 781.684.9827.

Read more at GlobeNewswire: Syndax Pharmaceuticals Reports Inducement Grants Under